Accessibility Menu
Hutchmed (China) logo

Hutchmed (China)(NASDAQ) HCM

Market Cap$1.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-20%
5 Year-74%
1 Year-41%
1 Month+0%
$10.79
-5.27%
-0.60Today
Hutchmed (China) last closing stock price
MetricPriceDate
Last closeUSD 10.772026-07-30
Hutchmed (China) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.73%USD 10.962026-07-23
1 month+0.09%USD 10.762026-06-30
3 month-19.02%USD 13.302026-05-01
Year to date-19.2%USD 13.332025-12-31
1 year-41.18%USD 18.312025-07-30
3 year-23.45%USD 14.072023-07-31
5 year-74.39%USD 42.052021-07-30
Since inception-20.22%USD 13.502016-03-18

Hutchmed (China) Financials at a Glance

Market Cap

$1.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$548.51M

Net Income (TTM)

$456.91M

EPS (TTM)

$2.62

P/E Ratio

4.11

Dividend

$0.00

Beta (Volatility)

1.13 (Average)

Price

$10.79

Volume

59,675.828

Open

$11.10

Previous Close

$10.77

Daily Range

$10.62 - $11.21

52-Week Range

$9.77 - $18.30

Estimated Earnings Date

Jul 2, 2026

HCM News

featured-transcript-logo

Hutchison China MediTech Limited (HCM) Q2 2019 Earnings Call Transcript

Motley Fool TranscriptionJul 30, 2019
Chart going down with man looking

Why Chi-Med Stock Is Tanking Today

Keith SpeightsJun 28, 2019

HCM: Motley Fool Moneyball Superscore

57

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hutchmed (China)

HUTCHMED (China) Limited is a biopharmaceutical firm focused on the discovery, development, and commercialization of innovative targeted and immune-based therapies for various cancers and immune-related disorders. The company operates primarily in oncology and immunology, with a diverse pipeline of products aimed at addressing significant unmet medical needs.

Products and Services
  • Developing Savolitinib for non-small cell lung cancer and other cancers
  • Fruquintinib targeting colorectal and gastric cancers
  • Surufatinib for neuroendocrine tumors and solid tumors
Growth Outlook
  • Strong pipeline with multiple candidates in late-stage clinical trials
  • Strategic collaborations with major pharmaceutical companies enhance market reach
  • Focus on expanding global presence beyond Hong Kong
Financial Highlights
  • Recent quarterly revenue of 135.4 million, showing stable performance
  • TTM net income margin of 83.3%, indicating strong profitability potential
  • Current ratio of 4.96, reflecting solid liquidity position
HUTCHMED (China) Limited is positioned in the healthcare sector, specifically within drug manufacturing for specialty and generic markets. The company has a robust pipeline that includes several promising therapies targeting various cancers, which could significantly impact its future revenue streams. Recent financial performance indicates a stable revenue base, with a notable net income margin that suggests effective cost management and operational efficiency. The company's strong liquidity position further supports its ability to invest in research and development, ensuring continued innovation and growth. With strategic partnerships and a focus on expanding its global footprint, HUTCHMED presents an intriguing opportunity for investors interested in the biopharmaceutical sector.
AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1,796

CEO

Chig Fung Cheng

Website

www.hutch-med.com

Headquarters

Hong Kong, HK

HCM Financials

Key Financial Metrics (TTM)

Gross Margin

11.64%

Operating Margin

-7.14%

Net Income Margin

83.30%

Return on Equity

37.04%

Return on Capital

-4.10%

Return on Assets

26.06%

Earnings Yield

24.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

174.47M

Volume

59.68K

Avg. Volume

51.49K

Financials (TTM)

Gross Profit

$63.87M

Operating Income

-$39.16M

EBITDA

-$25.85M

Operating Cash Flow

-$64.66M

Capital Expenditure

-$14.15M

Free Cash Flow

-$78.81M

Cash & ST Invst.

$1.37B

Total Debt

$97.89M

Hutchmed (China) Performance Analysis

Hutchmed (China) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 425,902,33719.4%
20232023-12-31USD 837,270,55596.6%
20242024-12-31USD 630,517,095-24.7%
20252025-12-31USD 549,962,669-12.8%
Hutchmed (China) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-14.4%
Q22025-06-30N/A
Q32025-09-30-2.5%
Q42025-12-31N/A
Hutchmed (China) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.1373.0%
20232023-12-31USD 0.58N/A
20242024-12-31USD 0.22-62.7%
20252025-12-31USD 2.621113.2%
Hutchmed (China) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-312923.3%
Q22025-06-30N/A
Q32025-09-30-100.0%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$135.42M

-16.5%

Gross Profit

-$23.12M

+17.9%

Gross Margin

-17.07%

N/A

Market Cap

$1.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.05M

N/A

Employees

1,796

N/A

Net Income

$977.50K

-83.6%

EBITDA

-$14.23M

-181.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$1.37B

+63.5%

Total Debt

$97.89M

+9.0%

Accounts Receivable

$147.83M

-11.9%

Inventory

$41.13M

-18.4%

Long Term Debt

$70.04M

+10.3%

Short Term Debt

$27.85M

+5.9%

Return on Assets

26.06%

N/A

Return on Invested Capital

-2.72%

N/A

Free Cash Flow

$1.68M

-89.7%

Operating Cash Flow

$4.12M

-79.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BHCBausch Health Companies Inc.
$6.03+28.85%
MLYSMineralys Therapeutics, Inc.
$26.19-0.61%
PRGOPerrigo Company plc
$10.31-1.10%
SUPNSupernus Pharmaceuticals, Inc.
$45.61-2.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About HCM

What is the current price of Hutchmed (China)?

Hutchmed (China) is trading at $10.77 per share.

What is the 52-week range for Hutchmed (China)?

Over the past 52 weeks, Hutchmed (China) has traded between $9.77 and $18.30.

How much debt does Hutchmed (China) have?

As of the most recent reporting period, Hutchmed (China) reported total debt of $97.89M.

How much cash does Hutchmed (China) have on hand?

Hutchmed (China) reported $71.33M in cash and cash equivalents in its most recent financial results.

What is Hutchmed (China)’s dividend yield?

Hutchmed (China) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services